Plasma thrombin activatable fibrinolysis inhibitor and tissue factor pathway inhibitor changes following sepsis

Clinical and Applied Thrombosis/Hemostasis

Volumn 13, Issue 4, 2007, Pages 362-368

  Ravindranath, Thyyar M ^a,b   Goto, Masakatsu ^b,c   Iqbal, Omer ^d   Florian Kujawski, Michelle ^d   Hoppensteadt, Debra ^d   Hammadeh, Rashid ^d   Sayeed, Mohammad M ^b,c   Fareed, J ^c  

^a CHILDREN S HOSPITAL OF NEW YORK   (United States)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

^c Burn and Shock Trauma Institute   (United States)

^d LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Burn; Ciprofloxacin; CLP; Polymicrobial sepsis; TAFI; TFPI

Indexed keywords

CIPROFLOXACIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TISSUE FACTOR PATHWAY INHIBITOR; LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY SURFACE; CECUM; CONTROLLED STUDY; ENTEROCOCCUS FAECALIS; FIBRINOLYSIS; HISTOLOGY; KIDNEY FUNCTION; LIGATION; LIVER FUNCTION; MALE; NONHUMAN; PARENCHYMA; PRIORITY JOURNAL; RAT; SEPSIS; ANIMAL; BACTERIAL INFECTION; BLOOD; GRAM NEGATIVE INFECTION; KIDNEY; LIVER; MICROBIOLOGY; PATHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; CARBOXYPEPTIDASE U; CIPROFLOXACIN; ENTEROCOCCUS FAECALIS; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; KIDNEY; LIPOPROTEINS; LIVER; MALE; RATS; RATS, SPRAGUE-DAWLEY; SEPSIS;

EID: 35748975414     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029607305580     Document Type: Article

References (17)

1. Vallet B. Bench to bedside review: endothelial cell dysfunction in severe sepsis: a role in organ dysfunction ? Crit Care. 2003 ; 7: 130-138.
2. Opal SM, Esmon CT Bench to bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Crit Care. 2003 ; 7: 23-38.
3. Morris PE, Hite RD, Ohl C. Relationship between the inflammation and coagulation pathways with severe sepsis: implications for therapy with activated protein C Biodrugs. 2002 ; 16: 403-417.
4. Bouma BN, Mosnier LO Thrombin activatable fibrinolysis inhibitor (TAFI) at the interface between coagulation and fibrinolysis. Pathophysiol Haemost Thromb. 2003 ; 33: 375-381.
5. Broze GJ Jr. The rediscovery and isolation of TFPI. J Thromb Haemost. 2003 ; 1: 1671-1675.
6. Nesheim M., Wang W., Boffa M., Naqashima M., Morser J., Bajzar L. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost. 1997 ; 78: 386-391.
7. ten Cate H. Pathophysiology of disseminated intravascular coagulation in sepsis. Crit Care Med. 2000 ; 28 (Suppl9). S9 - S11.
8. Miragliotta G. Endotoxin release after antibiotic treatment and its potential pathogenetic role in coagulative disorders of patients with gram-negative sepsis. J Chemother. 1991 ; 3 (Suppl 1). 69-72.
9. Taylor FB Jr. The inflammatory-coagulant axis in the host response to gram-negative sepsis: regulatory roles of proteins and inhibitors of tissue factor. New Horiz. 1994 ; 2: 555-565.
10. Rapaport SI The extrinsic pathway inhibitor: a regulator of tissue factor-dependent blood coagulation. Thromb Haemost. 1991 ; 66: 6-15.
11. Meijers JC, Oudijk EJ, Mosnier LO, et al. Reduced activity of TAFI (thrombin-activatable fibrinolysis inhibitor) in acute pro-myelocytic leukemia. Br J Haematol. 2000 ; 108: 518-523.
12. Asai S., Sato T., Tada T., et al. Absence of procarboxypeptidase R induces complement-mediated lethal inflammation in lipopolysaccharide-primed mice. J Immunol. 2004 ; 173: 4669-4674.
13. Golino P., Ragni M., Cimmino G., Forte L. Role of tissue factor pathway inhibitor in the regulation of tissue factor-dependent blood coagulation. Cardiovasc Drug Rev. 2002 ; 20: 67-80.
14. Kinasewitz GT, Yan SB, Basson B.,, et al. PROWESS Sepsis Study Group. Universal changes in biomarkers of coagulation and inflammation in patients with severe sepsis regardless of causative microorganism. Crit Care. 2004 ; 8 (2). R82 - R90.
15. Gando S., Kameue T., Morimoto Y., Matsuda N., Hayakawa M., Kemmotsu O. Tissue factor production not balanced by tissue factor pathway inhibitor in sepsis promotes poor prognosis. Crit Care Med. 2002 ; 30: 1729-1734.
16. Elsayed YA, Nakagawa K., Kamikubo YI, et al. Effects of recombinant human tissue factor pathway inhibitor on thrombus formation and its in vivo distribution in a rat DIC model. Am J Clin Pathol. 1996 ; 106: 574-583.
17. Hack CE, Zeerleder S. The endothelium in sepsis: source of and a target for inflammation. Crit Care Med. 2001 ; 29 (Suppl 7). S21 - S27.